echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > WHO launches "Solidarity Test+" to test 3 drugs

    WHO launches "Solidarity Test+" to test 3 drugs

    • Last Update: 2021-08-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    On August 11, local time, WHO held a routine press conference for new coronary pneumonia.


    At this stage, WHO will test three new drugs: artesunate (artesunate) for the treatment of severe malaria, the drug imatinib (imatinib) for the treatment of certain cancers, and for the treatment of the immune system Disorders such as infliximab (infliximab) in Crohn's disease


    Previously, the WHO initiated a "solidarity trial" at the global level, aiming to compare the safety and effectiveness of several different drugs or drug combinations in the treatment of new coronary pneumonia, in order to find effective treatments as soon as possible


    Focus on the new crown pneumonia epidemic
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.